



Raptor Pharmaceutical Corp.

NASDAQ: RPTP

www.raptorpharma.com

Raptor's mission is to research, produce, and deliver medicines that improve life for patients with severe and rare diseases. Starting with existing compounds with proven therapeutic activity and safety profiles helps Raptor potentially speed the delivery of new therapies to patients. Raptor is a NASDAQ-listed biopharmaceutical company with a product pipeline that may advance therapeutic options for 7 different indications and includes potential for product launch within the next 18 months.

Recent news

12/19/11: Raptor Pharmaceutical Corp. Signs Collaborative Research and Development Agreement With NIDDK on Phase 2b Clinical Trial of RP104 (DR Cysteamine Tablets) in Non-Alcoholic Steatohepatitis ("NASH")

09/13/11: Raptor Pharmaceutical Corp. Announces Closing of Public Offering of Common Stock

07/25/11: Raptor Pharmaceutical Meets Primary Endpoint in its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis

Clinical development pipeline

Raptor is developing RP103 (delayed-release cysteamine capsule) and RP104 (delayed-release cysteamine tablet) for the potential treatment of:

- Nephropathic Cystinosis (Phase 3 completed)
- Non-alcoholic Steatohepatitis (NASH) (Phase 2b planned)
- Huntington's Disease (Phase 2 ongoing)

Other clinical programs include:

- Convivia™ (oral 4-methylpyrazole) for the potential management of acetaldehyde toxicity due to ALDH2 deficiency, an inherited metabolic disorder
- Tezampanel, non-opioid glutamate receptor antagonists as a potential anti-platelet agent

Preclinical pipeline

Raptor is bioengineering novel drug candidates and a drug targeting platform derived from the human receptor-associated protein (RAP) and mesoderm development protein (Mesd) to target cancer and infectious diseases. These programs include HepTide™ and WntTide™.

Product	Preclinical	Phase 1	Phase 2	Phase 3
RP103 Delayed release cysteamine capsule	Nephropathic Cystinosis			
	Huntington's Disease			
RP104 Delayed release cysteamine tablet	Non-alcoholic Steatohepatitis (NASH)			

Business Development

Convivia Oral 4-methylpyrazole	ALDH2 Deficiency			
Tezampanel AMPA receptor antagonist	Thrombotic Disorders			

Preclinical Peptide-Based Delivery and Therapeutic Platforms

HepTide	Liver Delivery			
WntTide	Breast Cancer			



Collaborations

Raptor partners with leading research institutions and nonprofit organizations in an effort to expand the reach and benefit of established therapeutics.

Centre Hospitalier Universitaire d'Angers

The Cystinosis Foundation

**The Cystinosis Research Foundation
(Natalie's Wish)**

The Cystinosis Research Network

Huntington's Disease Society of America

Johns Hopkins University

**National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK), part of the National
Institutes of Health (NIH)**

Uni Pharma Co., LTD

University of Arizona

**University of California, San Diego
Medical Center**

University of Iowa

Washington University, St. Louis

Senior management

Christopher M. Starr, Ph.D.

Chief Executive Officer, Director & Co-founder

- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) co-founder

Ted Daley

President

- Founder and CEO, Convivia, Inc.

Patrice P. Rioux, M.D., Ph.D.

Chief Medical Officer

- CMO, FerroKin Biosciences
- CMO and VP, Clinical/Regulatory, Edison Pharmaceuticals

Todd C. Zankel, Ph.D

Chief Scientific Officer & Co-founder

- Sr. Director of Research, BioMarin

Kim R. Tsuchimoto

Chief Financial Officer, Secretary & Treasurer

- VP, Treasurer and VP, Controller, BioMarin

Patrick Reichenberger

VP, Commercial Operations

- Sr. Director of Commercial Development, XOMA (US) LLC

Kathy L. Powell

VP, Quality Operations

- VP, Quality, Pacific BioDevelopment

Market profile (01/04/12)

Ticker: NASDAQ: RPTP

Market capitalization: \$296.2M

Closing price: \$6.20

Avg. volume (3m): 438,000

52-week range:

Shares outstanding: 47.8M

52-week high: \$7.06

52-week low: \$3.10

Contacts

Raptor Pharmaceutical Corp.

Kim R. Tsuchimoto

Chief Financial Officer

415-382-1390

ktsuchimoto@raptorpharma.com

EVC Group

Media Relations

Janine McCargo

646-688-0425

jmccargo@evcgroup.com

The Trout Group

Investor Relations

Lauren Glaser

646-378-2972

lglaser@troutgroup.com

Raptor Pharmaceutical Corp.

9 Commercial Blvd., Suite 200

Novato, CA 94949

415-382-8111

www.raptorpharma.com

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the Company's ability to develop, obtain regulatory approval and commercialize its clinical and preclinical product candidate programs. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent our forward looking statements from coming to fruition include: that we may be unsuccessful in developing any products or acquiring products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission (the "SEC"), which we strongly urge you to read and consider, including our annual report on Form 10-K filed with the SEC on November 14, 2011, as amended on Form 10K/A filed with the SEC on December 19, 2011 and our quarterly report on Form 10-Q filed with the SEC on January 6, 2012, all of which are available free of charge on the SEC's web site at <http://www.sec.gov>. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our reports filed with the SEC. We expressly disclaim any intent or obligation to update any forward-looking statements.